Management of chemotherapy induced emesis

Management of chemotherapy induced emesis

Important progress has been achieved in the last few years in the prevention of chemotherapy-induced nausea and vomiting thanks to the introduction in clinical practice first of the 5-HT3 antagonists and of the NK1 antagonists more recently. To prevent acute emesis induced by cisplatin/moderately emetogenic chemotherapy, a combination of aprepitant plus a 5-HT3 antagonist and dexamethasone/a 5-...

Neuropharmacology of chemotherapy-induced emesis.

Sleep protects against chemotherapy induced emesis.

BACKGROUND We present a clinical trial to assess the hypothesis that chemotherapy related emesis is reduced when drugs delivered while the patient is sleeping. METHODS Adults without previous sleep disturbances of vomit inducing conditions who were going to receive their first courses of 100 mg/m2 cisplatin were included. We reduced antiemetic prophylaxis consisting of ondansetron and dexamet...

Management of Chemotherapy Induced Cardiomyopathy

Chemotherapy related cardiac dysfunction (CRCD) is a serious complication of anticancer therapy. CRCD can be classified into two types. Type I CRCD is exemplified by anthracyline- induced cardiac dysfunction and type II CRCD is exemplified by trastuzumab- induced cardiac dysfunction. The mechanism of cardiac toxicity in both types is not well defined. Certain risk factors may play a role in dev...

Audit of guidelines for effective control of chemotherapy and radiotherapy induced emesis.

A system was devised to establish the optimum treatment for emesis for each individual child receiving cytotoxic treatment. Cytotoxic drugs were ranked on a scale (1-5), with antiemetic regimens correspondingly graded. An age division (< or = 5 years, > 5 years) was included. Cytotoxic treatment was given with co-administration of the parallel antiemetic regimen. Failure to control emesis requi...